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ABSTRACT
Objectives Non-adherence to therapy is an important
cause of suboptimal blood pressure control but few
practical tools exist to accurately and routinely detect it.
We used a simple urine-based assay to evaluate the
prevalence of antihypertensive treatment non-adherence
and its impact on blood pressure in a specialist
hypertension centre.
Methods 208 hypertensive patients (125 new referrals,
66 follow-up patients with inadequate blood pressure
control and 17 renal denervation referrals) underwent
assessment of antihypertensive drug intake using high-
performance liquid chromatography-tandem mass
spectrometry (HP LC-MS/MS) urine analysis at the time
of clinical appointment. A total of 40 most commonly
prescribed antihypertensive medications (or their
metabolites) were screened for in spot urine samples.
Results Overall, 25% of patients were totally or
partially non-adherent to antihypertensive treatment
(total non-adherence 10.1%, partial non-adherence
14.9%). The highest prevalence of partial and total non-
adherence was among follow-up patients with
inadequate blood pressure control (28.8%) and those
referred for consideration of renal denervation (23.5%),
respectively. There was a linear relationship between
blood pressure and the numerical difference in detected/
prescribed antihypertensive medications—every unit
increase in this difference was associated with 3.0 (1.1)
mm Hg, 3.1 (0.7) mm Hg and 1.9 (0.7) mm Hg increase
in adjusted clinic systolic blood pressure, clinic diastolic
blood pressure (DBP) and 24 h mean daytime DBP
(p=0.0051, p=8.62×10−6, p=0.0057), respectively.
Conclusions Non-adherence to blood pressure
lowering therapy is common, particularly in patients with
suboptimal blood pressure control and those referred for
renal denervation. HP LC-MS/MS urine analysis could be
used to exclude non-adherence and better stratify further
investigations and intervention.
Non-adherence to pharmacological treatment is
recognised as an important barrier to the successful
management of many chronic disorders, including
hypertension.1 Poor concordance with treatment is
considered to be one of the major causes of
inadequate response to blood pressure (BP) lowering
treatment in patients diagnosed with ‘resistant hyper-
tension’ (up to 10%–20% of patients with high BP).2
This issue has recently come to the fore because of
the availability of new non-drug therapies, that is, per-
cutaneous radiofrequency, catheter-based renal sym-
pathetic denervation (renal denervation) for patients
with suspected resistance to antihypertensive treat-
ment.2 3 Furthermore, patients with undeclared/
unrecognised non-adherence frequently undergo
numerous additional (sometimes invasive and often
expensive) diagnostic tests in specialist centres to iden-
tify causes of their apparent poor response to antihy-
pertensive medications. Moreover, patients who are
non-adherent to antihypertensive treatment fail to
gain the proven beneﬁts of BP lowering therapy and
remain at high risk of cardiovascular events.4 5
The true prevalence of non-adherence to antihy-
pertensive treatment is not known. The published
data suggest that poor adherence may be more
common than full adherence to antihypertensive
therapy.5 6 The estimates of prevalence differ across
studies with non-adherence rates reported from as
low as 3% and up to 65%.7 One of the reasons for
this inconsistency is lack of direct and objective
methods to screen for and monitor non-adherence
to treatment among hypertensive patients.
Furthermore, demographic and clinical character-
istics (such as age, race, ethnicity, education, attend-
ance for clinical appointments, duration of
hypertension, coexistent comorbidities) are not or
only very poor correlates of adherence and cannot
provide accurate prediction of non-adherent behav-
iour.1 8 Clinical judgement is believed to overesti-
mate the rate of non-adherence to antihypertensive
treatment.9 Electronic methods of adherence moni-
toring (ie, computerised records of pharmacy pre-
scription reﬁlls, electronic records of pill box
opening or medication event monitoring systems)
may provide some insight into long-term persist-
ence with treatment and accurate timing of drug
administration. They were used in studies on anti-
hypertensive treatment.10 11 However, as heavily
dependent on patients’ behaviour (ie, opening a
box with medication may not always lead to its
administration in patients who choose to conceal
it), they are also imperfect proxies of adherence to
therapy.
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Here we report the data from high-performance liquid
chromatography-tandem mass spectrometry (HP LC-MS/MS)
analysis of spot urine samples to detect a wide range of most
commonly prescribed antihypertensive medications in >200
hypertensive patients attending a specialist clinical hypertension
centre (Leicester, UK). Apart from patients whose response to
clinic-prescribed BP lowering medications was suboptimal (sus-
pected non-adherence), we also examined new referrals from
primary care, as well as those referred for consideration of renal
denervation.
METHODS
Patients
A total of 208 hypertensive patients who underwent HP
LC-MS/MS biochemical screening for non-adherence to antihy-
pertensive treatment at the Leicester BP centre between
December 2011 and January 2013 were evaluated in this
project. They were divided into three separate groups (A, B and
C). A total of 125 individuals were new referrals from primary
care (Group A). They were screened for non-adherence to anti-
hypertensive therapy during their ﬁrst appointment in the clinic.
The only inclusion criterion of new patients in this project was
a referral letter from primary care. Suboptimal BP control was
one of the main but not the exclusive reason why patients from
Group A were referred to the clinic. Group B consisted of 66
patients whose BP response to clinic-prescribed antihypertensive
treatment was considered inadequate by a specialist in hyperten-
sion. All patients from Group B were under follow-up of the
centre and prior to inclusion into the study they had been
reviewed at least once in the clinic (on average ﬁve clinical
appointments prior to screening). Included in Group C were 17
hypertensive patients formally referred to our centre for consid-
eration of renal denervation. Their screening for adherence was
a part of a thorough diagnostic work-up prior to consideration
of this procedure. All patients in Group C had suboptimal BP
response to treatment based on clinical assessment of the refer-
ring clinician. The patients referred for renal denervation were
reviewed at least once in the clinic before test for therapeutic
non-adherence (average number of previous appointments— 7).
Basic demographic information (ie, age, sex, ethnicity) were
retrieved retrospectively from clinical ﬁles. Last seated clinic BP
values, measured according to the National Institute of Clinical
Excellence clinical guideline 127 using a validated semi-
automatic device (A&D Digital BP Monitor UA-767PC, A&D
Instruments) were recorded, prior to biochemical analysis of a
spot urine sample. Information on clinic BP was available for
204 patients. Information on 24 h ambulatory mean daytime BP
measured on the non-dominant arm (Spacelabs 90217A-1,
Spacelabs Healthcare) was available for 147 patients.
Urine analysis—HP LC-MS/MS
Spot urine samples for further biochemical testing were col-
lected in the morning on the day of the clinical appointment.
The samples were transferred from the clinic to the laboratory
at room temperature and stored at -70°C until further analysis.
Samples were prepared by solvent extraction and by dilution
technique. The dilution technique was used to detect strongly
polar drugs (such as lisinopril, nicorandil) that are difﬁcult to
extract. The samples were diluted in 1:10 in distilled water
before HP LC-MS/MS. Weekly acidic, basic and neutral antihy-
pertensive drugs (such as bisoprolol, diltiazem, amiloride)
underwent solvent extraction. In the extraction process, 5 mL of
urine was mixed with organic solvent for 10 min. It was then
centrifuged at 3000 rpm for 5 min. The upper organic layer was
evaporated under nitrogen at 40°C and reconstituted in 1 mL of
5% methanol prior to HP LC-MS/MS. Screening for lacidipine
and nebivolol required a prior hydrolysis step (5 mL of urine
incubated with 200 mL of β glucuronidase for 2 h at 60°C)
before further analysis.
HP LC-MS/MS was performed using an Agilent Technologies
1290 series High Pressure Liquid Chromatograph interfaced
with an Agilent Technologies 6460 Triple Quad Mass
Spectrometer ﬁtted with a Jetstream electrospray (ESI) source.
The nebuliser gas temperature was set at 350°C with a ﬂow of
5 L/min and a pressure of 45 psi. The sheath gas temperature
was set at 250°C and a ﬂow of 11 L/min. The HP LC system
was operated in gradient mode using 0.1% acetic acid in water
Table 1 Antihypertensive medications and/or their metabolites
examined in urine by high-performance liquid
chromatography-tandem mass spectrometry
No Antihypertensive medication (metabolites) Ion mode
1 Enalapril (enalaprilat) Positive
2 Lisinopril Positive
3 Perindopril (perindoprilat) Positive
4 Ramipril (ramiprilat) Positive
5 Quinalapril (qunilaprilat) Positive
6 Trandolapril (trandolaprilat) Positive
7 Candesartan (desethylcandesartan) Positive
8 Irbesartan (hydroxyirbesartan) Positive
9 Valsartan (hydroxyvalsartan) Positive
10 Losartan (losartan acid) Positive
11 Telmisartan Positive
12 Olmesartan Positive
13 Atenolol Positive
14 Metoprolol Positive
15 Propranolol Positive
16 Labetolol Positive
17 Bisoprolol Positive
18 Nebivolol (hydroxynebivolol) Positive
19 Amlodipine Positive
20 Felodipine Positive
21 Lercanidipine Positive
22 Lacidipine Positive
23 Nifedipine (hydroxynifedipinic acid, nifedipinic acid) Negative
24 Diltiazem Positive
25 Verapamil (norverapamil) Positive
26 Bendroflumethiazide Negative
27 Hydrochlorothiazide Negative
28 Indapamide Positive
29 Furosemide Negative
30 Chlorthalidone Positive
31 Bumetanide Positive
32 Eplerenone Positive
33 Spironolactone (canrenone) Positive
34 Amiloride Positive
35 Hydralazine Positive
36 Doxazosin (hydroxydoxazosin) Positive
37 Prazosin Positive
38 Moxonidine (dehydromoxonidine) Positive
39 Aliskiren Positive
40 Methyldopa Positive
Ion mode—depending on their chemical structure (positively or negatively charged
ions), antihypertensive medications or their metabolites were detected by positive or
negative ion mode scanning of the spectrometer, respectively.
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for mobile phase A and 0.1% acetic acid in methanol for mobile
phase B. The initial conditions of 5% B/ 95% A were held for
2 min and then ramped to 60% B at 6 min and further 100% B
at 9 min. The gradient was held at 100% B for 1 min and then
returned to 5% B at 11 min to re-equilibrate. The total run time
was 12 min per sample. An Agilent technologies Zorbax Eclipse
Plus C18 2.1×50 mm column was used for the HP LC
separation.
The mass spectrometer was operated in targeted multiple
reaction monitoring mode and each urine sample was analysed
twice, ﬁrst, in positive ion mode for drugs and metabolites
listed in category ‘Positive’ in table 1 and then in negative ion
mode for those listed under ‘Negative’ in table 1. A total of 40
antihypertensive medications or their metabolites were screened
for in urine (table 1).
Total non-adherence to antihypertensive treatment was
deﬁned as complete absence of any prescribed antihypertensive
medications (or their metabolites where appropriate) in a spot
urine sample on screening. Patients whose urine analysis con-
ﬁrmed the presence of fewer medications than prescribed were
classiﬁed as partially non-adherent.
The project was approved by the University Hospitals of
Leicester as an audit project (audit registration number: 5944).
Prior to screening, the patients were advised that their urine
sample would be assayed for presence of BP lowering drugs. As
a part of clinical care, the results of biochemical screening for
non-adherence to antihypertensive treatment were reported to
the patients (usually during their next appointment in the clinic)
and information on the results from HP LC-MS/MS urine-based
analysis was included in the clinical letter to patients’ general
practitioners.
Statistical analysis
Data are presented as counts/percentages, medians with
25%–75% IQR or means and SDs.
Analysis of association between BP and non-adherence to
antihypertensive treatment was conducted using multiple linear
regression models with BP as dependent quantitative variable
and age, sex, ethnicity, clinical category (new referrals,
follow-up patients, referrals for renal denervation) and thera-
peutic non-adherence (categorised into binary phenotype) as
independent parameters.
Further analyses of association between BP and quantitative
measures of non-adherence to treatment were carried out using
multiple linear regression models with BP as dependent quanti-
tative variable and age, sex, ethnicity, clinical category (new
referrals, follow-up patients, referrals for renal denervation) and
either the numerical difference or the ratio of detected/pre-
scribed antihypertensive medications as independent parameters
included in the regression models.
All analyses were conducted in STATA package.
RESULTS
The clinical characteristics of hypertensive patients are shown in
table 2.
Overall, 25% patients were totally or partially non-adherent to
antihypertensive treatment (total non-adherence 10.1%, partial
non-adherence 14.9%) (table 3). The average number of antihy-
pertensive drugs detected on screening (median 2 (25%–75%
IQR: 1–3)) was lower than the number of drugs prescribed and
screened for (median 3 (25%–75% IQR: 2–4)) (table 3). Across
the three groups of patients, the highest percentage of total non-
adherence with antihypertensive treatment was among those
referred for renal denervation—almost one in four patients from
this group had none of the prescribed medications detected in
urine, that is, complete non-adherence (table 3). The prevalence of
complete non-adherence among new referrals to the clinic
(Group A) and follow-up patients (Group B) were lower at 8.8%
and 9.1% (table 2). However, their overall non-adherence
Table 3 Non-adherence to antihypertensive treatment among
hypertensive patients
Measure of non-adherence All Group A Group B Group C
N 208 125 66 17
Average number of screened
medications
3 (2–4) 3 (1–4) 4 (3–5) 3 (2–5)
Average number of medications
detected
2 (1–3) 2 (1–3) 3 (1–4) 2 (1–3)
Complete non-adherence 21 (10.1) 11 (8.8) 6 (9.1) 4 (23.5)
Partial non-adherence 31 (14.9) 12 (9.6) 19 (28.8) –
Any non-adherence 52 (25.0) 23 (18.4) 25 (37.9) 4 (23.5)
Data are counts and percentages or medians and 25%-75% IQR (in brackets).
Table 2 General demographic and clinical characteristics of hypertensive patients
Phenotype All Group A Group B Group C
n 208 125 66 17
Age (years) 56.7±16.0 55.5±17.8 57.4±13.4 62.7±8.4
Sex (M/F) 93/115 57/68 28/38 8/9
BMI (kg/m2)* 31.5±6.8 31.4±7.2 31.6±6.3 31.9±6.0
White European ethnicity 151 (72.6) 93 (74.4) 44 (66.7) 14 (82.4)
Clinical appointments before screening 5 (3–7)† – 5 (2–10) 7 (4–13)
Clinic SBP (mm Hg)‡ 163±24.5 160±24.5 168±24.3 168±22.1
Clinic DBP (mm Hg)‡ 92±16.3 90±15.1 95±18.8 94±13.3
24 h daytime SBP (mm Hg)§ 154±20.1 151±19.7 160±19.5 160±21.0
24 h daytime DBP (mm Hg)§ 87±13.4 86±13.3 91±13.4 89±13.5
Group A—new referrals, Group B—follow-up patients with inadequate blood pressure control, Group C—patients referred for renal denervation.
*Body mass index (BMI)—data available for 185 patients.
†Average values for Groups B and C only, data are counts (number of individuals, sex) or counts and percentages (white European ethnicity), means and SDs (age, BMI, clinic blood
pressures, 24 h daytime blood pressures) or median and 25%–75% quartiles (clinical appointments before screening).
‡Clinic systolic blood pressure (SBP) and diastolic blood pressure (DBP)—data available for 204 patients.
§24 h daytime SBP and DBP—data available for 147 patients.
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(complete and partial non-adherence) was calculated at 18.4% and
37.9% (Groups A and B, respectively).
After adjustment for age, sex, ethnicity and clinical category
(new referrals, follow-up patients, referrals for renal denerv-
ation), clinic systolic blood pressure (SBP) and diastolic blood
pressure (DBP) as well as 24 h mean daytime DBP were higher
in non-adherent (either partially or completely) than fully
adherent patients (table 4). These differences were even more
striking when contrasting fully adherent against totally non-
adherent patients (table 4). There was a linear relationship
between BP and both the numerical difference and the ratio in
detected/prescribed medications—those with difference = 0 and
ratio = 1 (all medications taken and detected) had the lowest
clinic SBP, clinic DBP and 24 h mean daytime DBP (ﬁgure 1). As
a general trend, DBP showed a stronger association with non-
adherence to antihypertensive medications than SBP (table 4,
ﬁgure 1 and ﬁgure 2).
DISCUSSION
Our results revealed that one in four hypertensive patients
attending a specialist hypertension centre were partially or
totally non-adherent to pharmacological BP lowering therapy
on qualitative HP LC-MS/MS urine analysis. We also show that
biochemically conﬁrmed non-adherent hypertensive patients
have higher BP (in particular DBP) than those who adhere to
treatment. Furthermore, the data clearly demonstrate an associ-
ation between the degree of non-adherence to antihypertensive
treatment and clinic as well as 24 h daytime DBP values—the
higher the numerical difference (or lower the ratio) between
biochemically detected and prescribed medications, the higher
the BP. Finally, we showed that almost one in four patients
referred for renal denervation was completely non-adherent to
prescribed BP lowering treatment.
Our study is one of the ﬁrst to systematically use a robust
detection method to report the prevalence of non-adherence to
antihypertensive therapy among all new referrals to the special-
ist hypertension centre. Almost one in four of these patients
showed some degree of non-adherence and one in 10 were com-
pletely non-adherent to BP lowering therapy. A majority of
these patients in any secondary/tertiary care centre would rou-
tinely undergo many additional tests and procedures in search
of the explanation for their apparent unresponsiveness to stand-
ard therapy prescribed by primary care. Our data suggest that in
20% of such patients, these investigations (along with follow-up
appointments and exposure to unnecessary additional treat-
ment) could be potentially avoided if HP LC-MS/MS urine ana-
lysis was used as a routine screening for non-adherence.
Based on a similar methodology, a recently published survey
of 76 hypertensive patients with treatment resistance referred
from primary care to an out-patient nephrology centre showed
higher (≈50%) rate of non-adherence to BP lowering therapy.12
This difference may be explained by the different inclusion cri-
teria between both studies. Indeed, Jung et al12 screened only
patients with resistant hypertension while a majority of patients
included in this study were consecutive, unselected referrals
from primary care (Group A). The data from our investigation
are based on a larger and clinically more diverse sample of
hypertensive patients with a wider range of reasons for referral
to the clinic. This better reﬂects the true clinical spectrum of
patient population in a specialist hypertension centre. We
should also note the apparent difference in the average number
of prescribed antihypertensive medications between Jung et al
and our study (ﬁve vs three). The higher number of BP lowering
agents may also explain (at least to some extent) the higher rate
of non-adherence in the study by Jung et al given that complex
regime of prescribed medications is a recognised risk factor of
non-adherent behaviour.13
To the best of our knowledge, we are the ﬁrst to report the
rate of non-adherence to antihypertensive treatment among
patients referred for renal denervation. What is striking about
our ﬁndings in this group is their average rate of complete non-
adherence. Although non-adherence is a recognised cause of
resistant hypertension,2 the rates of true non-adherence to anti-
hypertensive therapy were either not reported or reported sub-
optimally in clinical trials on this group of patients.14–16 The
data collected in our audit suggest that as many as one in four
patients referred for renal denervation would not have qualiﬁed
for the procedure according to existing guidance on its use
which excludes non-adherence to therapy.17 18 Of course, it
could be argued that renal denervation could be the ideal treat-
ment for persistently non-adherent patients given their lack of
acceptance for regular administration of antihypertensive pills.
However, at present we would not recommend that renal
denervation is offered to non-adherent hypertensive patients.
First, currently there is no evidence for the clinical beneﬁts of
this intervention in therapeutically non-adherent patients.
Second, the existing data suggest that renal denervation may
reduce the number of antihypertensive medications but unlikely
to cure hypertension completely and as such may not be attract-
ive enough option for patients who choose not to take any BP
lowering medications (ie, all non-adherent patients in our renal
denervation group). Third, in a substantial proportion of
patients, non-adherence may be driven by fear of and/or certain
beliefs around potential side effects of treatment. While stop-
ping unwanted/unacceptable BP lowering medication is usually
Table 4 Association between blood pressures and non-adherence to antihypertensive treatment among hypertensive patients
Blood pressure Adherent Any non-adherent Complete non-adherent Beta (SE)* p Value* Beta (SE)† p Value†
Clinic SBP‡ 161±24.0 170±24.7 177±28.5 −9 (3.7) 0.0209 −18 (5.4) 0.0010
Clinic DBP‡ 90±14.4 100±19.1 107±18.3 −9 (2.4) 0.0003 −16 (3.5) 1.0×10−5
24 h daytime SBP§ 152±19.8 159±21.1 165±17.3 −6 (4.2) 0.1814 −14 (5.5) 0.0146
24 h daytime DBP§ 86±13.1 94±13.0 100±9.8 −6 (2.6) 0.0286 −11 (3.2) 0.0006
*Difference between adherence and any non-adherence (both partial and complete) after adjustment for age, sex, ethnicity and clinical category.
†Difference between adherence and complete non-adherence after adjustment for age, sex, ethnicity and clinical category.
‡Systolic blood pressure (SBP) and diastolic blood pressure (DBP)—information available for 152 adherent, 52 any non-adherent and 21 completely non-adherent patients.
§24 h daytime SBP and DBP—information available for 121 adherent, 26 any non-adherent and 15 completely non-adherent patients, data in columns 2–4 are means and SDs of
absolute blood pressure values recorded by clinic measurements and 24 h ambulatory blood pressure monitoring. Beta—β-coefficient, p value—level of statistical significance; all from
adjusted linear regression models with blood pressure as dependent quantitative variable and age, sex, ethnicity and clinical category (new referrals, follow-up patients, referrals for
renal denervation) as well as non-adherence to antihypertensive treatment as independent parameters included in the model.
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Figure 1 Association between blood
pressures and the numerical difference
between detected and prescribed
antihypertensive medications in all
hypertensive patients. Point data are
absolute blood pressure values
recorded on either clinic or 24 h
ambulatory monitoring, p value—
adjusted (for age, sex, ethnicity and
clinical category (new referrals,
follow-up patients, referrals for renal
denervation)) level of statistical
signiﬁcance for every unit change in
blood pressure per unit change in the
difference between detected and
prescribed antihypertensive
medications.
Figure 2 Association between blood
pressures and the numerical ratio of
detected and prescribed
antihypertensive medications in all
hypertensive patients. Point data are
absolute blood pressure values
recorded on either clinic or 24 h
ambulatory monitoring, p value—
adjusted (for age, sex, ethnicity and
clinical category (new referrals,
follow-up patients, referrals for renal
denervation)) level of statistical
signiﬁcance for every unit change in
blood pressure per unit change in the
ratio of detected and prescribed
antihypertensive medications.
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sufﬁcient to eliminate these perceptions, renal denervation while
generally safe is irreversible. Therefore, it may be difﬁcult to
convince such non-adherent patients and/or their managing clin-
icians to consider this mode of treatment.
Our study has several limitations. First, information on 24 h
ambulatory BP lowering was not available for approximately
25% of included patients. The lower number of observations
(and thus lower power to detect association) probably explains
somewhat the weaker relationship between non-adherence to
treatment and 24 h daytime BP values when compared with
clinic BP measurements. Second, the group of patients referred
for renal denervation was small. We also acknowledge several
imperfections of the method used as a screening of adherence
to treatment; that is, a single spot urine analysis may not fully
account for periodicity (both personal and seasonal)7 of non-
adherence to treatment. Furthermore, intuitively, one might
expect some patients to better adhere to treatment on the day of
clinic attendance (the so-called ‘tooth brush effect’19), given that
poor BP control in clinic is likely to prompt further investiga-
tion and/or treatment escalation. Thus, the spot urine assay may
underestimate chronic or intermittent non-adherence. However,
this limitation applies to the majority of currently used adher-
ence tests conducted in the clinic prior to appointments.
Repeated urine tests could provide a better insight into patients’
adherence to antihypertensive therapy. We also recognise the
unavailability of indirect measures of adherence to antihyperten-
sive treatment in this project. Further studies on utility and cost
effectiveness of HP LC-MS/MS urine analysis should be con-
ducted against indirect measures of adherence to inform future
health policies and clinical practice. Finally, this analysis was
conducted as an audit of adherence and we acknowledge the
risks of potential bias from unmeasured confounders in an
observational study.
However, biochemical screening for adherence to antihyperten-
sive treatment using a spot urine sample has several major advan-
tages. First, it is a completely non-invasive procedure that can be
conducted by a healthcare assistant prior to routine clinical
appointments. Unlike many other previously used methods of
screening, the HP LC-MS/MS analysis provides a clear ‘Yes/No’
answer to a question on presence/absence of antihypertensive
medications based on direct measurement of urine. Although the
costs of HP LC-MS/MS analyser are not trivial (≈£150 000),
many major clinical centres have access to such technology, a
single urine test is relatively inexpensive (approximately £30) and
the results can be provided quickly as sample processing takes
about 3 h. Moreover, the frozen samples are stable when stored
prior to biochemical analysis. Finally, HP LC-MS/MS is a recog-
nised method with good to excellent sensitivity and speciﬁcity to
detect many pharmacological agents in urine.20–22
CONCLUSIONS
In summary, our data provide a unique insight into the preva-
lence of non-adherence to antihypertensive treatment using an
objective and direct detection of BP lowering medications in
urine by HP LC-MS/MS. We show that a signiﬁcant proportion
of patients in a specialist centre show at least some degree of
treatment non-adherence and that their BP levels correlate well
with the degree on non-adherence. Finally, within the con-
straints of a small sample size, we show for the ﬁrst time alarm-
ingly high levels of complete biochemical non-adherence to
treatment among patients referred for renal denervation. Future
large multi-centre studies will be needed to provide estimates of
direct biochemical non-adherence to treatment in other popula-
tions and evaluate the cost effectiveness of this screening
method in the context of overall expenditure for management
of resistant hypertension. Further investigations should also
examine if discussing the results of HPLC-MS/MS-based screen-
ing with patients has a potential to improve their adherence to
antihypertensive treatment and, ultimately, BP control.
Key messages
What is already known on this subject?
Non-adherence to antihypertensive treatment is a recognised
cause of poor blood pressure control and ‘pseudo-resistant’
hypertension.
What this study adds?
Our data show that approximately one in four patients in a
specialist hypertension clinic is at least partially non-adherent to
blood pressure lowering treatment. We are the ﬁrst to report the
high prevalence of directly measured non-adherence to
antihypertensive treatment in a group of patients referred for
renal denervation.
How might this impact on clinical practice?
Screening for non-adherence to antihypertensive treatment by
high-performance liquid chromatography-tandem mass
spectrometry-based urine analysis is a simple, non-invasive
diagnostic test with a potential to better stratify patients prior
to treatment escalations and expensive and irreversible
procedures such as renal denervation.
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